The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Update is part of normal business. Being available to answer questions from share holders.... err why would that be considered to be special.
If CV not complete, I can’t see Al shedding light on the situation given past waffle.
Having some one answer mail rather than ignore. If the only mails coming were “is it ready yet” I can’t see why they wouldn’t just continue to ignore. Wishful thinking but maybe new questions such as which markets are the biggest, what is the next drug conjugate in the pipe, and can you help me, 40ft or 45 boat are on the cards.
Saw this yesterday too. Looks like more than one corner being turned.
Do you have Janices number, asking for a friend.
in the security check that fired up, the address in the url resolves to RedPaint, a web design agency which would point that yeah a product launch in on the way. Wonder if it will be beige, pink, or a lovely teal colour.
I think the LFD will be good as it gets but just cos Elisa works doesn’t mean it would work in LFD. Elisa molecules can meet and attach easily. No where near knowing the details, I could easily be wrong but in LFD Affimers are static and grab as thing come past in right orientation. But underlying tech is a great foundation.
What gives me confidence is the figures we had recently and some people who are way more into the details than me signing deals. They will have more info and understanding than we. But I am
Excited too.
He was always so sunny
lovebug1...wholly agree, even if UK stopped needing test tomorrow, market is huge for the next year or more. And even when cases fall to zero, the threat is big enough that testing will be needed in many situations eg entry into any hospital.
Half listened to the webinar yesterday.
DV working with aptamer group and a small mass spec machine.
Be interesting to ask why Avacta not involved, maybe they are but have enough fingers in the pie not to need more speculation in news. Maybe the license being negotiated for bams is exclusive.
Don’t know enough about the topic, and also half asleep. But also something different from the other RNS.
Ahhh as if by magic it fixed. Wtf?
Odd this change, who would have thought having a president who is willing to listen to science rather than Fox would make a difference. Wow
Are some posts missing from this thread. Says 7 but can only see 4???
Lse forum tech, it’s a world of its own
diagnostics....
prove it works, prove it can be made, license, the heavy lifting is global sales. avacta hasn't got a global sales team.
agentB,
affimer could grab biological marker molecules, they are then analysed in a mass spec machine. Deep verge AI figures out the tune from the noise.
nice innovation, wonder if IP can be protected. In a few years time a medical would be cough twice, pee in this pot, breath in this tube. You are good to go. Give it a few more year and Bones will have a little hand held swirly thing he runs over your body. Seriously, if it works, it could change diagnostics and catch things early. Be cool of affimers are the capture solution.
glad to see the potential is caught the markets eye.....errrr red number ????
bump, it made me laugh
Bugger my spell check, hope it raises a smile
I suspect Gerry would love UK contract but looks at the team in charge and figures there only so much you can do.
But that the UK is talking about it means it’s likely similar stories across the world (France, Italy, Indonesia,Costa Rica, St Kits). Adds another piece to a large jigsaw. why such a negative reaction to a post which adds to the bugger picture.
more likely that, as was said in video, the quality and consistency of a batch for something on a sniffle stick is different from that for something you inject in you.
I think drugs are manufactured under stricter controls than medical devices, and hence Avacta uses third party expertise. Great, it's a commodity value, why spend money developing that capability, until it hit meaningful volumes. The value is in the IPR not the machines making tablets. Not an expert, just a feeling.
?
To be fair you have a point, but the worth the investment or not depends on risk tolerance. Would I bet the house.... no. Enough to hurt but a win will change my retirement plans.....yes.
The critism has foundation, but realistically other companies take as long. So yeah cut the PR speel
and stick to facts.
Avacta and to some extent AIM is like public VC calls. High risk, high gain. The main market has sold me lower risk, more mature/experienced stocks/ceos
VC not unusual to provide stock options for workers who are likely working their nads off to realize your investment.